PremiumThe FlyCapricor Therapeutics reports Q4 EPS (16c), consensus (9c) Capricor Therapeutics options imply 8.9% move in share price post-earnings Promising Long-Term Efficacy of Capricor’s Deramiocel in DMD Spurs Buy Rating PremiumThe FlyCapricor Therapeutics options imply 7.5% move in share price post-earnings Target reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz Capricor Therapeutics: Promising Developments and Strategic Positioning Drive Buy Rating PremiumThe FlyCapricor completes BLA on time, requests priority review, says H.C. Wainwright Capricor Therapeutics completes submission of BLA to FDA for deramiocel Capricor, Gilead, Kymera, Praxis among Oppenheimer’s top biotech picks for 2025 
